Patritumab Deruxtecan Biologics License Application For Patients With Previously Treated Locally Advanced Or Metastatic Egfr-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

• PATRITUMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN

AsiaJapanese stocksNorth AmericaReutersUS stocks

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Show more

Login or create a forever free account to read this news

Let's go

---

More news from Reuters